AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- The European Journal of Nuclear Medicine & Molecular Imaging has published positive imaging data for RAD201.
- RAD201, the company’s HER2 nanobody, is being studied in patients with breast cancer.
- The company mentioned the publication as an excellent commendation of RAD201 technology, providing them added confidence to further develop this asset.
- The publication validates earlier data regarding the safety profile for the use of RAD201 in humans.
Radiopharm Theranostics (ASX:RAD), an oncology space player specialising in radiopharmaceutical products, has provided an upbeat update regarding its HER2 nanobody (RAD201). The renowned European Journal of Nuclear Medicine & Molecular Imaging has published positive imaging data regarding RAD201.
Triggered by the update, share price of RAD gained nearly 4.5% to trade at AU$0.115 apiece in the early hours of 13 December 2022.
RAD Chief Executive Officer & Managing Director, Riccardo Canevari highlighted the publication as an excellent commendation of RAD201 technology, boosting the company’s confidence to further develop this asset.
Below are the major underlies of the publication:
RAD201 has a favourable biodistribution and showed high accumulation in all active HER2-positive tumor sites.
It exhibited a high target-to-background ratio, promising tumor targeting and rapid blood clearance.
To conclude, the publication highlighted RAD201 as a ‘promising non-invasive tool for discriminating HER2 status in metastatic (breast) cancer, regardless of ongoing HER2-targeted antibody treatment’. This is due to the ability of RAD201 to bind to a different part of the HER2 receptor. It also validates earlier data regarding the safety profile for the use of RAD201 in humans.
© 2022 Kalkine Media®, Data and image source: Company update
Recently, the company reported motivating additional data provided by Imperial College London on brain metastases imaging trial on F-18 Pivalate (RAD 101). RAD 101 is the lead product candidate for brain metastases.